Sanofi Shs Sponsored American Deposit Receipt Repr 1/2 Sh $56.08

down -1.21


23/9/2014 02:25 PM  |  NYSE : SNY  
Industries : Drugs / Drugs - Generic
Get Trend Analysis Icon Get SNY Trend Analysis - it has underperformed the S&P 500 by 4%

Partner Headlines

  1. International Securities For A Diversified Income Portfolio

    GuruFocus
  2. Could European Funds Offer An Opportunity Now?

    Benzinga
  3. Meet 5 Top International Stocks Not Based In China

    IBD
  4. ReceptosMS Drug Yields More Good Data; Stock Jumps

    IBD
  5. Salix, Gilead Among 5 Top Medical Leaders To Watch

    IBD
  6. ECB Decision Boosts ETFs

    Benzinga
  7. Novartis, Regeneron Cardio Results Pump Up Wall St.

    IBD
  8. Novartis, Regeneron Hit New Highs On Cardio Drugs

    IBD
  9. Thin Gains Quickly Turn Mixed; Regeneron, Staples Surge Ahead

    IBD
  10. Nasdaq, S&P 500 Rise In Lackluster Session; Tesla Gains

    IBD
  11. Nasdaq Leads Quiet, Pre-Holiday Session; NXP Breaks Out

    IBD
  12. Gilead, Jazz Among 4 Top Big Cap Medicals To Watch

    IBD
  13. The 4 Companies Teaming Up For A New Tool To Fight Cancer

    Benzinga
  14. InterMune Stock Spikes On Rare Big Biotech Buyout

    IBD
  15. Guru Stocks at 52-Week Lows: CHL, TM, SNY, NVO, TSM

    GuruFocus
  16. Illumina Joins Drugmakers To Make Cancer Test System

    IBD
  17. Illumina lines up key partners

    IBD
  18. Illumina Forms Partnerships With Big Pharma Firms

    IBD
  19. Stocks Open Higher, Turn Mixed; Illumina Rises, Autohome Slips

    IBD
  20. Evaluating MannKind (MNKD) & Sanofi (SNY) Agreement for Afrezza

    GuruFocus
  21. Intermune up on buyout buzz

    IBD
  22. Benzinga's M&A Chatter for Wednesday August 13, 2014

    Benzinga
  23. Stocks Higher, Nasdaq Leads; Kinder Morgan, Priceline Rising

    IBD
  24. US Stock Futures Signal Higher Start On Wall Street

    Benzinga
  25. Pfizer To Buy Baxter's Vaccines For $635 Million: The Positives & Negatives

    Benzinga
  26. Glaxo, Sanofi Trend Up On Potential Deal For Established Brands

    Benzinga
  27. Amgen Cancer Drug Kyprolis Succeeds In Trial

    IBD
  28. Len Schleifer's Science Focus Pays Off At Regeneron

    IBD
  29. UPDATE: Sanofi Posts Upbeat Q2 Earnings, Lifts Profit Outlook

    Benzinga
  30. Amgen Restructuring Plan, Q2 Earnings Send Stock Up

    IBD
  31. Sanofi

    IBD
  32. Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest ...

    Benzinga
  33. Stocks Recover Impressively; Gap Slumps In After Hours

    IBD
  34. Regeneron's Dupilumab Drug Headed For Phase Three Tests

    IBD
  35. Market Slides On European Bank Worries; Gold Stocks Rise

    IBD
  36. Benzinga's Top #PreMarket Gainers

    Benzinga
  37. UPDATE: Regeneron, Sanofi Offer Positive Results from Phase 2b Study of ...

    Benzinga
  38. Jazz, Novo Among Medicals Showing Healthy Action

    IBD
  39. Pharmas Soar To New Highs

    IBD
  40. Salix, Akorn, Regeneron Lead Drug Stock Rally

    IBD
  41. Stocks Rise In Strong Turnover; Netflix Soars On Upgrade

    IBD
  42. Regeneron Rises As Sanofi Raises Stake In Biotech

    IBD
  43. Merrimack Pharmaceuticals Reaches Agreement With Sanofi, Regains Rights ...

    Benzinga
  44. Novo Nordisk Raises Insulin Prices As Demand Grows

    IBD
  45. Health Care Sector in an Upward Climb in June

    GuruFocus
  46. US Stock Futures Edge Higher Ahead Of Jobless Claims, Retail Sales Data

    Benzinga
  47. Top Held European Stocks Highlighted by Health Care and Oil and Gas Stocks

    GuruFocus
  48. Oakmark Funds' Bill Nygren Buys 4 New Stocks

    GuruFocus
  49. Eli Lilly insulin trial succeeds

    IBD
  50. Eli Lilly's Basal Insulin Outperforms Lantus In Trial

    IBD
Trading Center